September 5th, 2014
The Editors present a distillation of reader comments on a popular post.
September 1st, 2014
Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.
August 30th, 2014
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
October 22nd, 2012
This week’s topics include favorable lipid-level trends in U.S. adults, an angiotensin receptor neprilysin inhibitor for patients with HF and preserved systolic ejection fraction, and a long-term safety comparison of the Zotarolimus-eluting and Sirolimus-eluting coronary stents.